Cargando…

Serum levels of mac-2 binding protein are associated with diabetic microangiopathy and macroangiopathy in people with type 2 diabetes

INTRODUCTION: Non-alcoholic fatty liver disease is reportedly associated with type 2 diabetes and progressive liver fibrosis, as evaluated by transient elastography, and has been linked with micro- and macroangiopathy in people with type 2 diabetes. The purpose of this cross-sectional study was to i...

Descripción completa

Detalles Bibliográficos
Autores principales: Hashimoto, Yoshitaka, Hamaguchi, Masahide, Kaji, Ayumi, Sakai, Ryosuke, Kitagawa, Noriyuki, Fukui, Michiaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7451284/
https://www.ncbi.nlm.nih.gov/pubmed/32847841
http://dx.doi.org/10.1136/bmjdrc-2020-001189
_version_ 1783574948144480256
author Hashimoto, Yoshitaka
Hamaguchi, Masahide
Kaji, Ayumi
Sakai, Ryosuke
Kitagawa, Noriyuki
Fukui, Michiaki
author_facet Hashimoto, Yoshitaka
Hamaguchi, Masahide
Kaji, Ayumi
Sakai, Ryosuke
Kitagawa, Noriyuki
Fukui, Michiaki
author_sort Hashimoto, Yoshitaka
collection PubMed
description INTRODUCTION: Non-alcoholic fatty liver disease is reportedly associated with type 2 diabetes and progressive liver fibrosis, as evaluated by transient elastography, and has been linked with micro- and macroangiopathy in people with type 2 diabetes. The purpose of this cross-sectional study was to investigate the association between serum mac-2 binding protein glycosylation isomer (M2BPGi) levels and diabetic complications in people with type 2 diabetes. RESEARCH DESIGN AND METHODS: Serum M2BPGi levels were measured in terms of cut-off index (C.O.I.) units. Urinary albumin excretion (UAE) was calculated and nephropathy was graded as normoalbuminuria, microalbuminuria, or macroalbuminuria. Retinopathy was divided into three groups: no-diabetic retinopathy (NoDR), non-proliferative-diabetic retinopathy (NPDR), or proliferative-diabetic retinopathy (PDR). RESULTS: The mean age for the 363 studied subjects (212 males) was 66.4±10.6 years, the median serum M2BPGi level was 0.77 (0.57–1.04) C.O.I., and the median UAE was 22 (9–82.1) mg/g creatinine. M2BPGi levels in microalbuminuria (0.83 (0.61 to 1.18) C.O.I.) and macroalbuminuria (0.88 (0.67 to 1.22) C.O.I.) cases were higher than those in normoalbuminuria cases (0.71 (0.54 to 0.92) C.O.I.). M2BPGi levels in NPDR (0.93 (0.68 to 1.28) C.O.I.) and PDR (0.95 (0.71 to 1.31) C.O.I.) cases were higher than in cases with NoDR (0.73 (0.56 to 0.99) C.O.I.). Furthermore, M2BPGi levels in subjects with a history of cardiovascular diseases were higher than in those with no such history (0.82 (0.65 to 1.22) vs 0.76 (0.55 to 1.03) C.O.I., p=0.019). The logarithm of (M2BPGi+1) was associated with the logarithm of UAE values after adjusting for covariates (standardized β=0.107, p=0.031). CONCLUSIONS: This study reveals a close association between serum M2BPGi levels and diabetic microangiopathy and macroangiopathy in people with type 2 diabetes. The results also show that liver fibrosis, evaluated by M2BPGi, is independently associated with an increased risk of albuminuria.
format Online
Article
Text
id pubmed-7451284
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-74512842020-09-02 Serum levels of mac-2 binding protein are associated with diabetic microangiopathy and macroangiopathy in people with type 2 diabetes Hashimoto, Yoshitaka Hamaguchi, Masahide Kaji, Ayumi Sakai, Ryosuke Kitagawa, Noriyuki Fukui, Michiaki BMJ Open Diabetes Res Care Cardiovascular and Metabolic Risk INTRODUCTION: Non-alcoholic fatty liver disease is reportedly associated with type 2 diabetes and progressive liver fibrosis, as evaluated by transient elastography, and has been linked with micro- and macroangiopathy in people with type 2 diabetes. The purpose of this cross-sectional study was to investigate the association between serum mac-2 binding protein glycosylation isomer (M2BPGi) levels and diabetic complications in people with type 2 diabetes. RESEARCH DESIGN AND METHODS: Serum M2BPGi levels were measured in terms of cut-off index (C.O.I.) units. Urinary albumin excretion (UAE) was calculated and nephropathy was graded as normoalbuminuria, microalbuminuria, or macroalbuminuria. Retinopathy was divided into three groups: no-diabetic retinopathy (NoDR), non-proliferative-diabetic retinopathy (NPDR), or proliferative-diabetic retinopathy (PDR). RESULTS: The mean age for the 363 studied subjects (212 males) was 66.4±10.6 years, the median serum M2BPGi level was 0.77 (0.57–1.04) C.O.I., and the median UAE was 22 (9–82.1) mg/g creatinine. M2BPGi levels in microalbuminuria (0.83 (0.61 to 1.18) C.O.I.) and macroalbuminuria (0.88 (0.67 to 1.22) C.O.I.) cases were higher than those in normoalbuminuria cases (0.71 (0.54 to 0.92) C.O.I.). M2BPGi levels in NPDR (0.93 (0.68 to 1.28) C.O.I.) and PDR (0.95 (0.71 to 1.31) C.O.I.) cases were higher than in cases with NoDR (0.73 (0.56 to 0.99) C.O.I.). Furthermore, M2BPGi levels in subjects with a history of cardiovascular diseases were higher than in those with no such history (0.82 (0.65 to 1.22) vs 0.76 (0.55 to 1.03) C.O.I., p=0.019). The logarithm of (M2BPGi+1) was associated with the logarithm of UAE values after adjusting for covariates (standardized β=0.107, p=0.031). CONCLUSIONS: This study reveals a close association between serum M2BPGi levels and diabetic microangiopathy and macroangiopathy in people with type 2 diabetes. The results also show that liver fibrosis, evaluated by M2BPGi, is independently associated with an increased risk of albuminuria. BMJ Publishing Group 2020-08-26 /pmc/articles/PMC7451284/ /pubmed/32847841 http://dx.doi.org/10.1136/bmjdrc-2020-001189 Text en © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/ http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Cardiovascular and Metabolic Risk
Hashimoto, Yoshitaka
Hamaguchi, Masahide
Kaji, Ayumi
Sakai, Ryosuke
Kitagawa, Noriyuki
Fukui, Michiaki
Serum levels of mac-2 binding protein are associated with diabetic microangiopathy and macroangiopathy in people with type 2 diabetes
title Serum levels of mac-2 binding protein are associated with diabetic microangiopathy and macroangiopathy in people with type 2 diabetes
title_full Serum levels of mac-2 binding protein are associated with diabetic microangiopathy and macroangiopathy in people with type 2 diabetes
title_fullStr Serum levels of mac-2 binding protein are associated with diabetic microangiopathy and macroangiopathy in people with type 2 diabetes
title_full_unstemmed Serum levels of mac-2 binding protein are associated with diabetic microangiopathy and macroangiopathy in people with type 2 diabetes
title_short Serum levels of mac-2 binding protein are associated with diabetic microangiopathy and macroangiopathy in people with type 2 diabetes
title_sort serum levels of mac-2 binding protein are associated with diabetic microangiopathy and macroangiopathy in people with type 2 diabetes
topic Cardiovascular and Metabolic Risk
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7451284/
https://www.ncbi.nlm.nih.gov/pubmed/32847841
http://dx.doi.org/10.1136/bmjdrc-2020-001189
work_keys_str_mv AT hashimotoyoshitaka serumlevelsofmac2bindingproteinareassociatedwithdiabeticmicroangiopathyandmacroangiopathyinpeoplewithtype2diabetes
AT hamaguchimasahide serumlevelsofmac2bindingproteinareassociatedwithdiabeticmicroangiopathyandmacroangiopathyinpeoplewithtype2diabetes
AT kajiayumi serumlevelsofmac2bindingproteinareassociatedwithdiabeticmicroangiopathyandmacroangiopathyinpeoplewithtype2diabetes
AT sakairyosuke serumlevelsofmac2bindingproteinareassociatedwithdiabeticmicroangiopathyandmacroangiopathyinpeoplewithtype2diabetes
AT kitagawanoriyuki serumlevelsofmac2bindingproteinareassociatedwithdiabeticmicroangiopathyandmacroangiopathyinpeoplewithtype2diabetes
AT fukuimichiaki serumlevelsofmac2bindingproteinareassociatedwithdiabeticmicroangiopathyandmacroangiopathyinpeoplewithtype2diabetes